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Background: Oral tacrolimus therapy is effective for refractory ulcerative colitis (UC), but dose adjustment according to
the trough concentrations which varies largely among individuals, is required. This study aimed to identify factors to
predict the tacrolimus dose required for achieving the target trough level for remission induction of UC.
Methods: Forty-seven consecutive UC patients who were treated with tacrolimus were retrospectively analyzed.
Tacrolimus doses were adjusted every 2 or 3 days to achieve trough concentrations of 10–15 ng/mL. The dose required
for reaching the target trough level was analyzed based on disease characteristics, course of trough concentrations,
and gene polymorphism related to tacrolimus metabolism.
Results: Median daily dose of tacrolimus required for achieving the target trough level was 0.19 (0.07-0.42) mg/kg,
and patients were divided into high or low dose group (< 0.2 mg/kg or > 0.2 mg/kg). The value of initial trough
concentration/starting dose was higher in the low dose group than in the high dose group (1.35 ng/mL/mg vs.
0.78 ng/mL/mg, p < 0.0001). Although presence of CYP3A5 *1 was more frequently observed in the high dose
group, initial trough concentration was the only significant factor for determining requirement of high dose of
tacrolimus (OR = 28.0, 95% confidence interval 3.20 – 631).
Conclusions: The most practical predictor of the dose required for achieving the target trough concentration was
the trough concentration measured 2 or 3 days after starting tacrolimus therapy. Our findings would make
tarcolimus administration for UC safer, easier and more effective.
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Ulcerative colitis (UC) is an idiopathic chronic inflam-
matory disorder characterized by manifestations such as
diarrhea, rectal bleeding, abdominal pain, fever, anemia,
and body weight loss [1]. 5-aminosalicylates (5-ASA) are
the basic therapeutic drug, and most patients with mild to
moderate UC respond to them. Corticosteroid treatment
is considered in patients with more severe symptoms
when 5-ASA are not effective. However, intravenous* Correspondence: sakikoh@cc.okayama-u.ac.jp
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unless otherwise stated.steroids are not effective in 20-30% of patients, and these
patients ultimately are likely to require colectomy [2].
Calcineurin inhibitors such as cyclosporine A and ta-
crolimus have been shown to be effective for treatment
of steroid-dependent or steroid-refractory UC patients
with moderate to severe activity. Both of the medications
were effective for approximately 80% of refractory UC
patients [3-7]. To maximize the efficacy, however, these
drugs require adjustment of the doses for administration
by routinely measuring blood concentrations. To avoid
substantial fluctuation in the blood concentrations of
cyclosporine, it has to be administered by continuous
intravenous infusion. On the other hand, tacrolimus is
usually taken orally with sufficient efficacy by monitoring
trough blood concentrations of the drug. However, a large. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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trough levels among individuals has made the administra-
tion of tacrolimus difficult.
Tacrolimus is metabolized primarily by cytochrome
P450 3A4 (CYP3A4) and CYP3A5, and converted to a
substrate of ATP-binding cassette sub-family B member 1
(ABCB1) [8,9]. It has been reported that single-nucleotide
polymorphisms (SNPs) of CYP3A4, CYP3A5, and ABCB1
are correlated with altered pharmacokinetics of tacrolimus
in patients with organ transplantation [10,11]. Subjects
having the CYP3A5 *1 allele express large amounts of
CYP3A5 protein which promote metabolism of tacrolimus
[11]. In the treatment of UC, Hirai et al. recently reported
that a SNP of CYP3A5 was correlated with not only the
period and sufficient dose required for reaching the target
trough concentration, but also efficacy of tacrolimus ther-
apy [12]. In clinical settings, however, it is not practical to
examine SNPs before tacrolimus administration because
of the cost and clinical unavailability. Moreover, whether
patients should be treated with tacrolimus is determined
regardless of presence of the SNPs because the treatment
options for refractory UC are limited. In this context, easy
and practical methods to predict optimal dose of tacroli-
mus for achieving sufficient trough levels are eagerly
anticipated.
In this study, therefore, we meticulously examined the
courses of trough concentrations of tacrolimus in UC
patients who were administered tacrolimus as remission
induction therapy, and aimed to identify predictive
factors for the dose of tacrolimus required to achieve




Data on all patients with moderate to severe UC who
were treated with tacrolimus at Okayama University
Hospital and Wakayama Medical University Hospital
from September 2006 to October 2012, were analyzed.
A diagnosis of UC was established by the presence of
accepted clinical, endoscopic, and histologic criteria. No
patients had any renal function disorders, and if patients
received tacrolimus therapy twice or more, only the
initial administration episode was included in the ana-
lysis. This study was approved by the institutional review
board of both institutions. Ethics Committee of Okayama
University Graduate School of Medicine, Dentistry and
Pharmaceutical Sciences and Wakayama Medical Univer-
sity approved the study protocol including DNA analysis
(IRB No.218), and written informed consent was received
from each patient. There were no conflicts of interest or
sponsors of this study.
Medical charts provided clinical information including
demographic data, such as age, gender, and duration ofthe disease, as well as disease status, such as severity of
disease, extent of disease, and medications. According
to Truelove and Witts’ criteria [13], all patients had
either moderate or severe disease, and all were steroid-
dependent or steroid-refractory. Steroid-dependency was
defined as the inability to completely withdraw systemic
steroids because of disease relapse or the occurrence of at
least two flare-ups requiring systemic steroid therapy in a
six-month period. Steroid-refractoriness indicated little or
no improvement after two weeks of systemic steroid ther-
apy (at least 30 mg prednisolone daily).
As candidates of predictive parameters, concomitant
medications (5-ASA, corticosteroids, immunomodulator
(azathioprine or 6-mercaptopurine) use), bowel movement
(frequency/day), diet (fasting or not), and laboratory data
including leukocyte count, platelet count, hemoglobin,
and C-reactive protein (CRP) at the start of tacrolimus
therapy were specifically examined. Tacrolimus dose was
analyzed with adjustment by body weight.
Administration and monitoring of tacrolimus
For patients who were treated with oral tacrolimus ther-
apy, capsules (Prograf; Astellas Pharma Inc., Tokyo, Japan)
containing 0.5 mg or 1 mg of tacrolimus were used. The
initial oral dose of tacrolimus was 0.05-0.15 mg/kg/day
twice daily. Whole blood trough concentration of tacroli-
mus was measured at each hospital once every 2–3 days
by the affinity column mediated immunoassay. The dose
of tacrolimus was adjusted in the evening according to the
trough concentration measured in the morning of the
same day. The target whole blood trough concentration
was 10–15 ng/mL and dose adjustment was done to
achieve the target concentration as soon as possible within
2–3 weeks [6,14,15]. For most of cases, adjustment was
made to reach the target within one week. The equations
for dose adjustment were as follows: previous dose ×
(10 ng/mL/blood trough concentration) until 3 days after
starting tacrolimus, and previous dose × (12.5 ng/mL/
blood trough concentration) more than 3 days after start-
ing tacrolimus.
All responding patients were followed by tapered blood
trough levels of 5–10 ng/mL for about 3–6 months.
Evaluation of efficacy of tacrolimus
The efficacy of tacrolimus was evaluated by criteria
based on changes in the clinical activity index (CAI)
scores proposed by Lichtiger et al [3]. Clinical courses
were classified as remission, response, and no response.
Remission was defined as a CAI score of 3 or lower
within 4 weeks of starting tacrolimus therapy. Response
was defined as a CAI score of 4 or higher, but equal to
or lower than half the score at the start of tacrolimus
therapy. ‘Effective’ case was defined as a patient either in
remission or with response. ‘No response’ was defined as
Table 1 Characteristics of study population
Total 47
Age, years, median (range)
at onset 30 (11–67)
at initiation of tacrolimus 40 (12–70)









Left-side colitis 13 (28%)
Concomitant therapy
5-ASA 42 (89%)
Corticosteroid use 42 (89%)
Immunomodulator use 13 (28%)
SNPs analysis
CYP3A5 (*1*1/*1*3/*3*3) 1/12/24
ABCB1 exon26 (CC/CT/TT) 15/14/8
The SNP analysis was performed only for patients who provided written
informed consent for this procedure.
SNPs, single-nucleotide polymorphisms 5-ASA, 5-aminosalicylic acid.
CYP3A5, cytochrome P450 3A4.
ABCB1, ATP-binding cassette sub-family B member 1.
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with response. All of these definitions were determined
regardless of steroid administration status, because rela-
tively short-term effect was evaluated in this study. Ad-
verse events of tacrolimus were counted when reduction
of the dose or discontinuation of tacrolimus was needed.
Analysis of SNPs of genes associated with tacrolimus
pharmacokinetics
Genetic analysis of CYP3A5 and ABCB1 polymorphisms
was performed according to previous reports [16]. In brief,
genomic DNA was extracted from peripheral blood using
the QiaAmp DNA Mini kit (Qiagen, Valencia, CA, USA).
We analyzed the polymorphisms of CYP3A5 (rs776746)
and ABCB1 exon 26 (rs1045642) genes using TaqMan®
SNP Genotyping Assay (Applied Biosystems, Foster City,
CA, USA) with a LightCycler 480 system, as recom-
mended by the manufacturer (Roche Diagnostics, Basel,
Switzerland).
Statistical analysis
We used the chi-square test or Fisher’s exact test for
univariate analysis and the logistic regression model for
multivariate analysis in order to identify factors contrib-
uting to the dose of tacrolimus required. Results are
shown with calculations for odds ratios (ORs) and 95%
confidence intervals (CIs). These analyses were per-
formed using the JMP program (version 8, SAS Institute,
Cary, NC, USA). To estimate appropriate cutoff values
for age, leukocyte count, platelet count, hemoglobin, and
CRP, receiver operating characteristic (ROC) curve ana-
lysis was performed. All p values were two-sided and
considered significant when less than 0.05.
Results
Clinical characteristics of patients
We administered tacrolimus to 47 UC patients during
the study period. Characteristics of the study population
are shown in Table 1. The patients included 24 (51%)
men and 23 (49%) women, with a median age of 40 years
(range; 12–70 years) at the initial administration of
tacrolimus treatment. All patients had either pancolitis
or left-side colitis. Forty-two (89%) patients used 5-ASA,
42 (89%) patients used corticosteroids, and 13 (28%) pa-
tients used immunomodulators (azathioprine (AZA) or
6-mercaptopurine (6-MP)). The disease duration of the
patients was 43.6 (0.74-336) months. Of these patients,
41 (87%) achieved clinical remission or response and 6
(13%) had no response with tacrolimus therapy.
The dose of tacrolimus required for the target trough level
Figure 1 shows a histogram of the tacrolimus dose re-
quired for reaching the target trough concentration
(mg)/body weight (kg) of the 47 patients. Median dailydose of tacrolimus required for the target trough level
(10–15 ng/mL) was 0.19 (0.07-0.42) mg/kg, and the largest
number of patients was distributed within the range from
0.15 to 0.20 mg/kg. Hence, the patients were divided into
two groups according to the required dose (low dose
group: < 0.2 mg/kg, or high dose group: > 0.2 mg/kg).
Table 2 shows the comparison of clinical characteris-
tics between patients of the low dose group and those
of the high dose group. Clinical and medical character-
istics did not differ significantly between the two
groups. Laboratory data at the start of tacrolimus ad-
ministration demonstrated that patients of the high
dose group tended to have higher CRP than patients of
the low dose group (2.20 (0.04-14.7) vs. 0.93 (0.02-
7.73), p = 0.053). The results of SNP analysis of genes
associated with tacrolimus pharmacokinetics indicated
that CYP3A5 *3*3 was significantly more frequently ob-
served in patients of the low dose group than in those
of the high dose group (19 (90%) vs 5 (31%), p = 0.001).
Clinical courses of patients in the low dose group vs. high
dose group
The time courses of the trough concentrations of the
patients in each group are shown in Figure 2. As shown
Figure 1 The distribution of the dose required for reaching the target trough concentration of tacrolimus/body weight. The median dose
required for reaching the target trough concentration of each patient was 0.19 mg/kg, and the peak of the distribution was 0.15 mg/kg – 0.20 mg/kg.
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in the high dose group increased gradually without out-
liers, some of the patients in the low dose group showed
excessive trough concentrations early after starting ta-
crolimus. In fact, the trough concentrations exceeded
20 ng/mL within 7 days after start of tacrolimus in 5/26
(19%) patients of the low dose group.
Table 3 shows the clinical courses of patients in the low
vs. high dose groups. The period required for reaching the
target trough concentration was significantly shorter in pa-
tients of the low dose group than in those of the high dose
group (5 (2–13) days vs. 7 (3–17) days, p = 0.011). In
addition, the percentage of patients who attained the target
trough levels within 7 days was higher in the low dose
group (88% vs. 62%, p = 0.043). Moreover, the period re-
quired for reaching remission was significantly shorter in
the low dose group than in the high dose group (14 (5–26)
days vs. 18 (13–42) days, p =0.0055), although the remis-
sion rate did not differ significantly between the two
groups. Adverse events that required discontinuation or
reduction of the drug occurred slightly more frequently in
patients of the low dose group, although statistical signi-
ficance was not observed (6/26 (23%) vs. 2/21 (10%),
p = 0.27). Details of the adverse events were nausea (3
patients), renal dysfunction (2 patients), and headache (1
patient) in the low dose group, while nausea (1 patient)
and fatigue (1 patient) in the high dose group. Thus, the
classification by our criteria (low dose group vs. high dose
group) appears to be reasonable, and if it could be pre-
dicted into which group a patient is classified, more appro-
priate dose modification could be tailored to each patient.
Predictors of the dose required for achieving the target
trough level
As shown in Figure 2, the trough levels measured early
from the start of tacrolimus therapy may differentiatebetween the low dose and high dose groups. In addition,
Table 3 indicates that the value of initial trough concen-
tration/starting dose was significantly higher in patients
of the low dose group than in those of the high dose
group (1.35 (0.50-3.60) vs. 0.78 (0.30-1.30), p < 0.0001).
Therefore, the early trough concentration, which can be
represented as the value of initial trough concentration/
starting dose of tacrolimus, is considered to be one of
the predictors of the dose required for achieving the
target trough level.
To precisely evaluate the correlation between the ini-
tial trough concentration and the required doses for the
target trough level, we analyzed 42 patients who under-
went initial measurement of the trough concentration at
2 or 3 days after starting tacrolimus. The median initial
trough concentration of those patients was 5.3 (0.9-20.5)
ng/mL, and the value of initial trough concentration/
starting dose of tacrolimus (ng/mL/mg) and the dose of
tacrolimus required for the target trough level/body
weight (mg/kg) were significantly inversely correlated
(R2 = 0.41, p < 0.0001) (Figure 3). All patients with a
value of initial trough concentration/starting dose (ng/
mL/mg) > 1.5 were categorized into the low dose group.
On the other hand, only one of 17 patients with a value
of initial trough concentration/starting tacrolimus dose
(ng/mL/mg) < 1.0 was placed into the low dose group.
An ROC analysis revealed that the value of initial trough
concnentraion/starting dose of 1.0 ng/mL/mg discrimi-
nated most precisely between the low and high dose
groups (AUC = 0.876). These results suggest that the
trough concentration at 2 or 3 days after starting tacro-
limus could be an indicator determining whether the
patient require high or low doses of tacrolimus.
Meanwhile, as shown in Table 2 and Figure 3, the
patients with CYP3A5 *1 allele (red dot) were more likely
to belong to the high dose group, while the patients
Table 2 The differences in clinical background between patients of the low dose group and the high dose group
Low dosea < 0.2 mg/kg High dosea ≥ 0.2 mg/kg Univariate analysis
n = 26 n = 21 p
Median(range) age at onset, years 36 (12–67) 31 (11–64) NS
Median(range) age at starting tacrolimus, years 42.5 (12–70) 36 (14–67) NS
Median(range) duration of disease, months 28.7 (0.74-336) 62.2 (0.97-323) NS
Gender
Male/Female 10/16 14/7 0.08
Disease severity
Moderate/Severe 20/6 14/7 NS
Extent of disease
Pancolitis/Left-side colitis 19/7 15/ 6 NS
Medications
5-ASA 25 17 0.16
Corticosteroid use 24 28 NS
Dose of corticosteroid at initiation of tacrolimus (PSL) 25 (0–40) 20 (0–30) 0.12
Immunomodulator use 8 5 NS
Bowel movement at initiation of tacrolimus (times/day) 8 (4–20) 7.5 (4–15) NS
Diet at initiation of tacrolimus
Fasting 6 6 NS
Laboratory data at initiation of tacrolimus
White blood cell count (×103/μL) 7.52 (4.71-15.0) 7.50 (5.46-15.2) NS
Hemoglobin (mg/dL) 11.2 (7.50-13.6) 10.4 (7.90-14.4) NS
Platelet count (×104/μL) 39.6 (9.70-65.6) 38.1 (12.0-75.2) NS
CRP (mg/dL) 0.93 (0.02-7.73) 2.20 (0.04-14.7) 0.053
SNPs analysisb
CYP3A5 (*1*1/*1*3/*3*3) 0/2/19 1/10/5 0.001
ABCB1 exon26 (CC/CT/TT) 9/8/4 6/6/4 NS
aPatients were divided into two groups by the maximum dose (<0.2 mg/kg or ≥ 0.2 mg/kg).




CYP3A5, cytochrome P450 3A4.
ABCB1, ATP-binding cassette sub-family B member 1.
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fied into the low dose group (presence/absence of CYP3A5
*1 allele: low dose group, 11/5 vs. high dose group, 2/19;
p = 0.0003). Therefore, the SNP of CYP3A5 is another
candidate predictor of the tacrolimus dose required for
achieving the target trough concentration.
Predictive values for patients requiring high tacrolimus
doses: the initial trough concentration vs. gene
polymorphism
As we have shown, two parameters, the initial trough
concentration and the SNP of CYP3A5, could predict
patients requiring high tacrolimus doses. Thus, we com-
pared the predictability between the two parameters
using multivariate analysis (Table 4). A value of initialtrough concentration/starting dose < 1 ng/mL/mg is a
significant predictor of patients requiring high doses of
tacrolimus (OR = 60.8, 95%CI 3.20-631), p < 0.0001). On
the other hand, SNP of CYP3A5 did not reach statistical
significance.
Discussion
Both of the calcineurin inhibitors, cyclosporine and tacro-
limus, have been shown to be effective for refractory UC
[3-7,12,14]. Whereas cyclosporine has to be administered
intravenously due to the variable nature of blood concen-
tration, tacrolimus can be used by peroral administration,
usually twice a day, with sufficient efficacy. It has been
reported that the optimal trough concentration of 10–
15 ng/mL should be attained ‘quickly and safely’ for
Figure 2 The courses of trough concentrations of tacrolimus in patients belonging to the high-dose group (A) and to the low dose group (B).
While the trough concentrations of patients in the high dose group increased gradually without outliers, some of the patients in the low dose
group showed excessive trough concentrations early after starting tacrolimus.
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reaching the target trough level differ largely among
patients, and therefore, management of the trough
concentrations is often difficult. Delay in reaching the
target trough level would also delay treatment response,
and may decrease the efficacy of the drug, whereas too
rapid increase in blood concentration could causeTable 3 Differences in the courses of tacrolimus therapy betw
Period required for reaching the target trough level (>10 ng/mL) of tacrolim
Patients who attained the target trough level (>10 ng/mL) within 7 days





Period required for reaching remission (day)
Adverse events
Required for discontinuation and reduce
aPatients were divided into two groups by the maximum dose (<0.2 mg/kg or ≥ 0.2
bTwo patients of the high dose group could not achieve the trough concentrationadverse events. In this study, to ease the administration
of tacrolimus, we looked for markers to predict the dose
required for achieving the target blood concentration
among materials already available in actual clinical
practice.
It is known that tacrolimus is metabolized primarily by
CYP3A4 and CYP3A5, and is converted to a substrate ofeen patients of the high dose group and low dose group
Low dosea High dosea p
n = 26 n = 21
us (day) 5 (2–13) 7 (3–17) b 0.011b
23 (88%) 13 (62%) 0.043
1.35 (0.50-3.60) 0.78 (0.30-1.30) <0.0001
18 (70%) 12(57%) NS
4 (15%) 7 (33%)
4 (15%) 2 (10%)
14 (5–26) 17.5 (13–27) 0.0055
6 (23%) 2 (10%) 0.27
mg/kg).
of 10 ng/mL. The analysis was performed excluding these two patients.
Figure 3 The relationship between initial trough concentrations and doses required for sufficient trough levels. The value of initial trough
concentration/starting dose of tacrolimus (ng/mL/mg) and the dose of tacrolimus / body weight (mg/kg) required for reaching the target trough
level were inversely correlated (R2 = 0.41, p < 0.001).
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CYP3A5 affected pharmacokinetics of tacrolimus and
the presence of the CYP3A5 *1 allele was a predictor of
requirement of high dose administration. Moreover, they
reported that patients without the CYP3A5 *1 allele were
more likely to enter remission with tacrolimus therapy.
In line with this report, we also showed that the SNP of
CYP3A5 affected pharmacokinetics of tacrolimus and
predicted the requiring dose of the drug to some extent.
However, examination of SNPs prior to prescription of
the drug is not practical due to the cost, unavailability at
hospitals, and ethical problems. Hence, we meticulously
analyzed the disease course and drug trough concentra-
tions of the patients who were treated with tacrolimus,
and found that the trough concentration measured 2 or
3 days after starting the treatment is a more precise pre-
dictor of dose requirement of the drug for remission in-
duction therapy. This predictor is very simple and canTable 4 Multivariate analysis of factors predictive for
requiring high tacrolimus doses (> 0.2 mg/kg)
Multivariate analysis
p
CYP3A5 (*1*1 or *1*3) 6.14 (0.61 - 66.8) 0.12
The initial trough concentration/
starting dose > 1 ng/mL/mga
28.0 (3.20 - 631) <0.0001
aTo estimate appropriate cutoff values, receiver operating characteristic (ROC)
curve analysis was performed.
CYP3A5, cytochrome P450 3A4.be used without any other examinations or parameters.
For instance, if a patient with body weight of 60 kg
started tacrolimus therapy with 6 mg/day, and the
trough concentration measured 2 or 3 days after initi-
ation was < 6 ng/mL, the dose should be increased to
12 mg/day. On the other hand, if the trough concentration
measured 2 or 3 days after initiation was > 6 ng/mL, the in-
crease of the dose should be minimized (Figure 4). Thus,
our results would be very useful in adjusting administra-
tion of tacrolimus for remission induction therapy in UC
patients.
Patients with the CYP3A5 *1 allele are rich in the
CYP3A5 protein and can metabolize tacrolimus more
efficiently. Therefore, the results regarding the require-
ment of a higher dose to reach the target trough concen-
tration in patients with CYP3A5 *1 allele appeared to be
consistent and corroborative with those of the previous
report by Hirai et al [12]. In contrast to the previous
report, however, the remission rate within 4 weeks did
not differ significantly between the two groups (13/24
(54%) vs. 10/13 (77%), p = 0.29). The discrepancy could
be attributable to the following reasons.
First, the patients in the report by Hirai et al. had
more severe disease than our cohort; all of their patients
were hospitalized, and the average CRP appeared to be
more than 5 mg/dL. In contrast, 14/47 (30%) of our
patients were outpatients, and the median CRP of our
patients was 1.4 mg/dL. Perhaps due to the difference in
severity, the total remission rate was higher in our study
Figure 4 The algorithm based on the earliest trough concentration. If a patient with body weight of 60 kg started tacrolimus therapy with 6 mg/day,
and the trough concentration measured 2 or 3 days after initiation was < 6 ng/mL, the dose should be increased to 12 mg/day. On the other hand,
if the trough concentration measured 2 or 3 days after initiation was > 6 ng/mL, the increase of the dose should be minimized
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The higher remission rate of our study was probably one
of the contributing factors for lack of statistical signifi-
cance between patients with and without the SNP. Sec-
ond, the frequency of adjustment of tacrolimus doses
may be different. We measured trough concentrations of
tacrolimus once every 2–3 days, while Hirai et al. ap-
peared to measure the trough concentration only twice,
on days 2–5 and 7–10, during the early period of ther-
apy. The frequent adjustment of the dose of tacrolimus
may have increased the remission rate of our patients.
Whether or not our easy method for predicting the dose
requirement of tacrolimus is valid in more severe UC
patients should be verified in future studies.
It is expected that our results would make the hand-
ling of tacrolimus easier and would expand the use of
the drug in the clinical situation. Because the treatment
tools for refractory UC are still limited, tacrolimus could
be a user-friendly option that would impact greatly on
the clinical practice for refractory UC patients in several
manners. First, while another calcineurin inhibitor,
cyclosporine, requires continuous intravenous infusion,
tacrolimus can be taken orally, indicating that the drug
can be prescribed for outpatients. Our results would
make the trough management of tacrolimus therapy for
outpatients easier and reduce the frequency of clinic
visits, possibly resulting in an increase in the success rate
of the treatment. Second, in current clinical situations,
anti-tumor necrosis factor alpha antibodies such as
infliximab and adalimumab are usually used for refrac-
tory UC outpatients. Although such agents have also
been shown to be effective for refractory UC patients
[17,18], those are injected agents, thus, patients have to
visit a clinic or hospital periodically for infusions or per-
form self-injection. In contrast, tacrolimus has an advan-
tage that it is a peroral drug and easily acceptable forevery type of patients. Third, appropriate management
of the blood concentration of tacrolimus would reduce
adverse events due to the drug. The relatively frequent
adverse events of tacrolimus are nausea, headache,
tremor, and renal dysfunction. Those events usually
occur when blood concentrations of the drug are too
high. In particular, nausea and headache are likely to
occur when the blood concentration abruptly increases.
Reduction of adverse events by appropriate monitoring
of the blood concentration as per our results would also
lead to increased success of the tacrolimus treatment.
The starting dose of tacrolimus for UC used in the
previous phase III study was 0.05 mg/kg/day [6,14]. In
this study, the average initial dose of tacrolimus was
0.10 mg/kg/day, although there was variation among
patients due to the retrospective cohort. As shown in
Figure 1, the dose required for the target trough level
was more than 0.10 mg/kg/day in 91% of patients, thus,
the initial dose of 0.10 mg/kg/day would be reasonable.
In this situation, however, patients of the low dose group
more frequently developed adverse events (23%) mostly
due to excessive trough concentrations, although most
of these events were mild. Therefore, our findings re-
garding the prediction of requirement of low or high
dose within 2 or 3 days after starting tacrolimus would
be helpful in view of avoidance of adverse events.
There are limitations to the present study. Because this
was a retrospective clinical study, the intervals of trough
measurement differed among patients. The initial trough
concentration was not measured at 2 or 3 days after
start of tacrolimus in several patients, and those patients
were not included in the corresponding analyses. Trough
management based on our results should be validated in
prospective studies in the future. The SNP analysis also
could not be performed in a few patients who did not
give approval for the analysis.
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We found that the initial trough concentration could
be a useful predictor of the dose of tacrolimus required
for remission induction therapy. The drug monitoring
based on our findings can be utilized in any situation of
clinical practice and does not need specific examina-
tions such as analysis of gene polymorphism. Our find-
ings would make tacrolimus therapy for refractory UC
patients more patient- and physician-friendly.
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